Details for Patent: 7,737,181

Summary for Patent: 7,737,181

Title:	Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Abstract:	Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Inventor(s):	Michael Graeber, Janusz Czernielewski
Assignee:	Galderma Research and Development SNC
Application Number:	US11/494,693
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound;

United States Patent 7,737,181 (Adapalene 0.3% Topical Gel/Cream/Lotion/Spray): Scope, Claim Architecture, and Competitive Patent Landscape

What does US 7,737,181 claim at the highest level?

US 7,737,181 is directed to topical dermatologic formulations for “common acne” in which:

• Adapalene is the only active anti-acne ingredient in the composition (repeated as a core limitation across all product forms).
• The formulation contains adapalene at 0.3% by weight in the specified dosage strength (claims 1, 6, 11, 16, 25, 28).
• The product is delivered in multiple vehicles:
  • Aqueous gel (claims 1-5, 35-36)
  • Aqueous cream gel (claims 6-10)
  • Cream (claims 11-15)
  • Aqueous lotion (claims 16-24, 34)
  • Spray solution (claims 25-28)

The claim set is built around a vehicle-and-excipient scaffold. The “hard wall” is adapalene identity + 0.3% + only-active constraint. The rest of the scope is carved by “consisting essentially of” limitations tied to specific polymer gels, emulsifiers, oils, and pH targets.

---

What is the core claim boundary created by “consisting essentially of” and “only active”?

Across the product-form claim families, the patent uses two interlocking constraints:

1. Only active anti-acne ingredient

   • Language appears explicitly in:
     • aqueous gel (claim 1)
     • cream gel (claims 6-8, 9-10)
     • cream (claim 11, 15)
     • aqueous lotion (claim 16, 20, 22, 24, 34)
     • spray solution (claims 25, 28)

2. Vehicle limited by “consisting essentially of”

   • This creates a scope that permits some additional excipients, but restricts inclusion of actives and limits what non-actives are allowed when they are outside the recited groups.
   • The patent also adds dependent claims that hard-code specific excipient lists and quantities, which function as “fallback” embodiments.

Practical implication for competitors: entry designs must avoid adding an additional acne-active (for example, benzoyl peroxide, topical antibiotics, salicylic acid as an acne-active, etc.) while also staying within or around the claimed vehicle excipient universe.

---

How are the claims organized by product form and strength?

The claims divide into five parallel formulation lines, each anchored on adapalene 0.3%:

Aqueous gel line

• Independent: claim 1 (aqueous gel; adapalene 0.3%; vehicle defined by eligible gel-medium ingredient classes)
• Vehicle-specific dependents:
  • claim 2 (fixed excipient set: Carbomer + preservatives + Poloxamer 124, propylene glycol, etc.)
  • claim 4 (fixed gel-medium ingredient set: Xanthan gum + Hydroxypropylethylcellulose + Poloxamer 124, etc.)
• Example-style quantitative formulations:
  • claim 3 (carbomer 940 + pH 5.0 ± 0.3)
  • claim 5 (Xanthan gum + Hydroxypropylethylcellulose + pH implied by vehicle)
• Additional gel-medium specificity:
  • claim 35 (at least one carbomer)
  • claim 36 (carbomer 940)

Aqueous cream gel line

• Independent: claim 6 (cream gel medium; adapalene 0.3%)
• Dependent vehicle:
  • claim 7 (Simulgel 600 PHA + cetearyl isononanoate + fixed additives)
• Quantitative embodiment:
  • claim 8 (Simulgel 600 PHA + cetearyl isononanoate; adapalene 3 mg per gram; q.s. 1 g)
• Alternative quantitative embodiments:
  • claim 9 (Pemulen TR1 + mineral oil)
  • claim 10 (Pemulen TR1 + mineral oil; pH 5.0 ± 0.3)

Cream line

• Independent: claim 11 (cream medium; adapalene 0.3%)
• Dependent broadening:
  • claim 12 (cream medium can contain silicone and non-silicone oil classes)
  • claim 13 (cream medium can contain specific oil/emollient sub-classes including perhydrosqualene and cyclomethicone)
• Quantitative embodiment:
  • claim 14 (explicit list including Carbomer 934, PEG-20 methyl glucose sesquistearate, cyclomethicone, perhydrosqualene; pH 6.5 ± 0.3)
  • claim 15 (Carbomer 934 + PEGs + glycerol + cyclomethicone + perhydrosqualene; pH 6.5 ± 0.3; fixed mg amounts)

Aqueous lotion line

• Independent: claim 16 (aqueous lotion medium; adapalene 0.3%)
• Dependent medium classes:
  • claim 17 (humectant/pro-penetrant/mineral oil/emulsifier class)
  • claim 18 (propyl glycol/glycerine/sorbitol/PEGs/mineral oil/perhydrosqualene/esters)
• Quantitative embodiment:
  • claim 20 (Simulgel 600 PHA + steareth 21 + glyceryl/PEG100 stearate; preservative system; pH 5.5 ± 0.5)
• Alternative vehicle hard-coded dependents:
  • claim 19 (ingredient list with Simulgel 600 PHA + steareth 21 + glyceryl/PEG 100 stearate)
  • claim 21 (Carbopol 981 NF and Ceteareth 20 system)
  • claim 22 (Carbopol 980/981 NF + ceteareth 20 + stearyl alcohol + caprylic/capric triglycerides + cyclomethicone; q.s. pH; explicit mg amounts)
  • claim 23 (EDTA system + Carbopols + specific sugar esters and poloxamer)
  • claim 24 (mirrors claim 22 vehicle list but structured as another “consisting essentially of” composition)
  • claim 34 (explicit % w/w lotion formula; adapalene 0.3; EDTA disodium + Carbopol 980/981 NF + methyl glucose sesquistearate + PEG-20 methyl glucose sesquistearate + dimethicone 20 cst + poloxamer 124 + propylene glycol; q.s. 100)

Spray solution line

• Independent: claim 25 (spray solution; adapalene 0.3% + caprilic/capric triglycerides as key medium component)
• Dependent medium broadening:
  • claim 26 (humectant/pro-penetrant, PEGs, lipophilic and oil classes)
  • claim 27 (caprilic/capric triglycerides + N-methylpyrrolidone + ethanol)
• Quantitative embodiment:
  • claim 28 (adapalene 0.3 + caprilic/capric triglycerides 50 + N-methylpyrrolidone 3 + ethanol q.s. 100)

---

What do the vehicle ingredient groups practically cover? (Claim 1 vehicle universe)

Claim 1 defines the aqueous gel medium using a class-based ingredient group, allowing at least one from:

• Carbomers
• Polymeric emulsifying agents
• Polysaccharidic biopolymers
• Gums
• Alginates
• Modified celluloses
• Starch derived products
• Mixtures of
  • polysorbate 80 + isohexadecane
• Acrylamide/sodium acryloyldimethyltaurate (polymer gelling system)

This is a broad formulation scaffold for gels. The dependent claims then pin to specific gelling systems and specific preservative/emulsifier frameworks.

---

How do pH targets function as claim-limiting structure?

Multiple embodiments specify pH windows that narrow product realization:

• Aqueous gel with carbomer 940: claim 3
  • pH 5.0 ± 0.3
• Aqueous cream gel with Pemulen TR1: claim 10
  • pH 5.0 ± 0.3
• Cream formulation: claim 14 and 15
  • pH 6.5 ± 0.3
• Aqueous lotion with Simulgel 600 PHA / steareth 21 system: claim 20
  • pH 5.5 ± 0.5

Competitor take: the patent contains both class-level coverage (claim 1, claim 16, claim 25) and tight embodiment-level pressure points (claims 3, 10, 14, 15, 20, 34). Even if designing around excipient lists, a pH window can become a practical “claim trigger” for obvious variants.

---

What is the claim set’s “hard” numeric coverage?

The patent repeatedly includes either mg-per-gram or % w/w numeric compositions. Key numeric anchors:

• Adapalene concentration

  • Aqueous gel: claim 1 states 0.3% by weight
  • Cream gel: claim 6 states 0.3% by weight
  • Cream: claim 11 states 0.3% by weight
  • Lotion: claim 16 states 0.3% by weight
  • Spray: claim 25 states 0.3% by weight
  • Quantified examples: claims 3, 8, 10, 15, 20, 22, 24, 28, 34 all reflect adapalene 3 mg/g or 0.30% w/w

• Vehicle-specific quantitative anchors

  • Gel (claim 3): carbomer 940 11 mg; propylene glycol 40 mg; pH 5.0 ± 0.3
  • Cream gel (claim 8): Simulgel 600 PHA 20 mg; cetearyl isononanoate 100 mg
  • Cream gel (claim 10): Pemulen TR1 5 mg; mineral oil 120 mg; pH 5.0 ± 0.3
  • Cream (claim 15): cyclomethicone 130 mg; perhydrosqualene 60 mg; pH 6.5 ± 0.3
  • Lotion (claim 20): Simulgel 600 PHA 1.00%; steareth 21 3.00%; glyceryl and PEG 100 stearate 3.00%; pH 5.5 ± 0.5
  • Spray (claim 28): caprilic/capric triglycerides 50%; N-methylpyrrolidone 3%; ethanol q.s.

Numeric specificity matters because “consisting essentially of” compositions can still be argued to cover ranges only if the claim language or prosecution history supports it. Here, many embodiments are locked to exact amounts.

---

What is the claim strategy: broad classes with “consisting essentially of” plus enumerated dependent fallbacks?

The architecture is typical of formulation IP:

• Independent claims (1, 6, 11, 16, 25) cover:

  • Product form (gel/cream gel/cream/lotion/spray)
  • Adapalene identity and dosage (0.3%)
  • Only-active constraint
  • Vehicle medium limited to enumerated ingredient classes or at least-one selections

• Dependent claims (2-5; 7-10; 12-15; 17-24, 34; 26-28) do three things:

  1. Define specific polymer/solvent/emollient systems
  2. Lock preservatives and surfactant choices
  3. Lock pH windows

• Inert additive dependent claims (29-33) add allowable excipient classes for each dosage form:

  • wetting agents, preservatives, stabilizers, moisture regulators, pH regulators, emulsifiers, UV screening agents, antioxidants, etc.

That set is designed to prevent easy design-around arguments like “we used a UV filter/preservative not listed elsewhere,” as long as the excipient is within those categories.

---

Does the patent cover alternative spray solution media beyond caprilic/capric triglycerides?

Claim 25 explicitly requires a spray solution medium comprising caprilic/capric triglycerides and states adapalene 0.3% with only-active constraint.

Claims 26 and 27 expand possible additional components:

• Claim 27 hard-codes the combination of caprilic/capric triglycerides + N-methylpyrrolidone + ethanol.

Claim 28 locks an “as marketed” quantitative formulation.

So, competitors that use different oils as the principal solvent/vehicle in a spray are less likely to land in the independent claim; they also face dependent claim limitations if they use the same solvent pairings.

---

Where is overlap likely with existing adapalene topical product formulations?

Even without inspecting prosecution details, the claim set maps directly onto widely used topical excipient families:

• Carbomer gels (Carbomer 940/934; Carbopol 980/981)
• Cellulose derivatives (Hydroxypropylethylcellulose)
• Natural gums (Xanthan gum)
• Non-ionic surfactants/emulsifiers (Poloxamer 124, Polysorbate 80)
• Thickened oil emulsions and gel-cream systems (Simulgel 600 PHA, Pemulen TR1, cetearyl isononanoate)
• Sugar-based emulsifiers (PEG-20 methyl glucose sesquistearate, methyl glucose sesquistearate)
• Skincare oil classes (perhydrosqualene, cyclomethicone)
• Lotion structures (Caprilic/capric triglycerides, Ceteareth 20, stearyl alcohol, dimethicone)

Overlap risk increases if competitors use:

• adapalene at 0.3%
• a gel/lotion/cream vehicle using the listed polymer and emulsifier families
• and avoid adding actives

This is not an “adapalene alone” patent. It is a vehicle-constrained adapalene 0.3% topical formulation patent.

---

What design-around routes are suggested by the claim boundaries?

Based purely on claim limitations:

1. Change the vehicle so it no longer fits the enumerated “consisting essentially of” medium limitations

   • The medium is constrained to recited classes and specific ingredient lists in dependent claims.

2. Keep adapalene as only active but avoid the specific pH/combination embodiments

   • pH windows and explicit quantitative compositions create leverage for arguing non-infringement when manufacturing specs deviate.

3. Change the delivery form outside the claimed categories

   • The patent enumerates gel, cream gel, cream, lotion, and spray solution. Alternate forms (other than those) may avoid claim capture.

4. Avoid caprilic/capric triglycerides as the defining spray medium component

   • Because claim 25 is anchored to caprilic/capric triglycerides in the spray medium.

These routes only matter if a competitor can still meet stability and efficacy without adding other acne-actives.

---

How should an investor or R&D team treat this patent in competitive planning?

US 7,737,181 is best modeled as a product-by-vehicle fence:

• It fences adapalene 0.3% topical acne formulations using specified gel/cream/lotion/spray excipient architectures.
• It creates strong barriers for competitors launching generic-style vehicles that remain within the same excipient and pH ecosystems.
• It does not prevent adapalene topical therapy generally; it constrains a specific combination of:
  • adapalene at 0.3%
  • no other acne actives
  • vehicle system within the claim-defined excipient universe

---

Key Takeaways

1. US 7,737,181 covers adapalene 0.3% topical acne formulations across gel, cream gel, cream, lotion, and spray solution.
2. The patent’s central limitation is “adapalene is the only active anti-acne ingredient” paired with vehicle restrictions under “consisting essentially of.”
3. The claim set uses broad independent claims (class-based excipient coverage) plus tight dependent fallbacks with fixed ingredient lists and pH windows (notably pH 5.0 ± 0.3, pH 5.5 ± 0.5, and pH 6.5 ± 0.3).
4. Spray coverage is anchored to caprilic/capric triglycerides; spray alternatives likely need different solvent oils to avoid the independent claim.
5. The inert additive dependents (claims 29-33) broaden allowable excipient categories, making “we included UV filters/preservatives” a weak design-around if the excipient category fits.

---

FAQs

1) What is the single most important infringement trigger in US 7,737,181?

Adapalene at 0.3% as the only active anti-acne ingredient, plus a vehicle that fits the claimed gel/cream/lotions/spray medium limitations.

2) Can a competitor add another acne active and still avoid the patent?

No. The claims repeatedly require adapalene as the only active anti-acne ingredient, so adding other acne actives conflicts with the claim language.

3) Which claims contain the most manufacturing-restrictive conditions?

The quantitative “consisting essentially of” embodiments and those specifying pH windows, including claims 3, 10, 14, 15, 20, and 34.

4) How does the patent treat inert additives like preservatives and UV filters?

It adds dependent claims that allow inert additives from specified categories (claims 29-33), reducing the risk that excipient choice alone avoids the patent if it stays within those categories.

5) Does the patent cover topical adapalene products beyond 0.3%?

The recited “anti-acne effective amount” is consistently tied to 0.3% by weight in the independent product-form claims and corresponding quantitative examples in dependents.

---

References

No external documents were cited in the prompt content.

Drugs Protected by US Patent 7,737,181

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,737,181

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

International Family Members for US Patent 7,737,181

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924
Austria	417610
Austria	432072
Australia	2003216898
Australia	2008203279
Brazil	0307550
Brazil	PI0307550